Lung Cancer Organoid Models

Advantages of Patient-derived Lung Cancer Organoid Models
By contrast, recently developed patient-derived organoid (PDO) models make up for these defects of 2D cultures and patient-derived xenograft (PDX) models and are physiologically and clinically more advanced, providing an unparalleled strategy for studying lung cancer and creating an opportunity to tailor therapies for individual patients.

Capture and retain the molecular, cellular, genetic, and histological phenotypes of the original tumor even better.
Maintain patient-specific tumor heterogeneity.
Show a short culture cycle and long-term in vitro expansion capability.